Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.68 |
| ▸ | PPARA | Q07869 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10946840 | 0.95 | PPARD (0.63) | PPARDPPARASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL23605980 | 0.90 | PPARA (0.75) | PPARDPPARASMN1; SMN2PTPN1PPARG | |
| SCHEMBL339492 | 0.83 | ALOX15 (0.81) | PPARDSMN1; SMN2ALDH1A1ALOX15PPARG | |
| SCHEMBL11525116 | 0.83 | ALDH1A1 (0.63) | PPARDPPARASMN1; SMN2ALDH1A1PTPN1 | |
| SCHEMBL12611856 | 0.83 | ALDH1A1 (0.63) | PPARDPPARASMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL11537941 | 0.83 | ALDH1A1 (0.63) | PPARDPPARASMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL6507086 | 0.83 | ALDH1A1 (0.68) | PPARDPPARASMN1; SMN2ALDH1A1MAOB | |
| SCHEMBL4642558 | 0.82 | SMN1; SMN2 (0.70) | PPARDPPARASMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL10944778 | 0.82 | LMNA (0.62) | SMN1; SMN2 | |
| SCHEMBL25201617 | 0.82 | CYP1A1 (0.75) | PPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2026042018-A1 | 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES | PFIZER INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025224599-A1 | PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2025-06-12 | — | — | US | disclosed |
| US-20250122159-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2025-04-17 | — | — | US | disclosed |
| US-12258338-B2 | Modulators of the integrated stress response pathway | EVOTEC INTERNATIONAL GMBH (DE) | 2025-03-25 | — | — | US | disclosed |
| WO-2025015167-A2 | ERASTIN KETONE ANALOGS AND USES THEREOF | EXARTA THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-12139478-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2002092590-A1 | FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | disclosed |
| US-4138577-A | 11-Deoxy-cis-4,5-didehydro-ω-aryl-PGF compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4138575-A | 11-Deoxy-16-phenoxy-PGF compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4138576-A | 11-Deoxy-2,2-difluoro-ω-aryl-PGF compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4138573-A | 11-Deoxy-2,2-difluoro-ω-aryl-PGE compounds | THE UPJOHN COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4126754-A | 11-Deoxy-cis-4,5-didehydro-ω-aryl-PGE compounds | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4086240-A | 1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones | VELSICOL CHEMICAL CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4053480-A | 1-THIADIAZOLYL-5-PHENOXY- AND PHENYLTHIOALKANOYLOXY IMIDAZOLIDINONES | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258338-B2 | Modulators of the integrated stress response pathway | CRHR2, CRHR1, CRH | PPARD 3727/4885PPARA 2924/4885SMN1; SMN2 2678/4885 |
| US-20250188071-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | CRHR2, CRHR1, CRH | PPARD 3727/4885PPARA 2924/4885SMN1; SMN2 2678/4885 |
| US-12139478-B2 | Compounds, compositions and methods | EIF4EBP1, EIF4B, EIF4E | PPARD 4503/4885PPARA 4568/4885SMN1; SMN2 1178/4885 |
| US-20260055057-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | PPARD 573/4885PPARA 558/4885SMN1; SMN2 4001/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | PPARD 4784/4885PPARA 4759/4885SMN1; SMN2 1990/4885 |
| US-20250326741-A1 | GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | GIPR, GLP1R, GPR119 | PPARD 410/4885PPARA 490/4885SMN1; SMN2 3204/4885 |
| US-20250122159-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | EIF4EBP1, EIF4B, EIF4E | PPARD 4503/4885PPARA 4568/4885SMN1; SMN2 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.